Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

Thorax

Volumn 52, Issue 11, 1997, Pages 987-993

  Conway, S P ^a   Pond, M N ^a   Watson, A ^a   Etherington, C ^a   Robey, H L ^b   Goldman, M H ^b  

^a SEACROFT HOSPITAL   (United Kingdom)

^b Pharmax Ltd   (United Kingdom)

Author keywords

Colistin; Cystic fibrosis; Nephrotoxicity; Neurotoxicity; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG INFECTION; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

EID: 0030783691     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.11.987     Document Type: Article

References (32)

1. Dodge JA, Morrison S, Lewis PA, Coles EC, Geddes D, Russell G, et al. Cystic fibrosis in the United Kingdom, 1968-88: incidence, population and survival. Paediatr Perinatol Epidemiol 1993;7:157-66.
2. Cystic Fibrosis Foundation. Patient registry: 1991 Annual Data Report. Bethesda, Maryland: 1992.
3. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991;46:881-5.
4. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
5. Hoiby N, Heilesen A, Moller NE. Development of Pseudomonas aeruginosa strains resistant to carbenicillin, azlocillin, piperacillin and tobramycin during chemotherapy in cystic fibrosis patients. Monogr Paediatr 1981;14:103-7.
6. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis clinic. J Antimicrob Chemother 1986;17:505-16.
7. Southern KW, Cunliffe CHE, McLaughlin SM, Haase EJ, Todd NJ, Littlewood JM. A review of the use of intravenous colistin in a regional cystic fibrosis unit. European Cystic Fibrosis Conference, Madrid, 1993: PD46.
8. Goldman M, Alcorn M. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by colistin. European Cystic Fibrosis Conference, Madrid, 1993: PD45.
9. Mouton JW, den Hollander JG, Horrevorths AM. Emergence of antibiotic resistance among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993;31:919-26.
10. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68.
11. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP Ann Pharmacother 1991;25:1168-70.
12. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive Treatment of Pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Pediatr Scand 1985;74: 107-13.
13. Shwachman H, Kulczycki LL. Long-term study of 105 patients with cystic fibrosis: studies made over a 5 to 14 year period. Am J Dis Child 1958;96:6-15.
14. Chrispin AR, Norman AP. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol 1974;2: 101-5.
15. Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ, Joanes DN, et al. The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 1994;49:860-2.
16. Froman J, Gross L, Curatola S. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 1970;103:210-4.
17. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-54.
18. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7.
19. Blessing J, Maybury B, Lewiston N. Antimicrobial susceptibility of Pseudomonas from sputum of patients: 1975 to 1980. Monogr Paediatr 1981;14:115-9.
20. Walinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med 1962;266:759-62.
21. Price DJE, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal function. BMJ 1970;4: 525-7.
22. Cox CE, Harrison LH. Intravenous sodium colistimethate therapy of urinary tract infections: pharmacological and bacteriological studies. Antimicrob Agents Chemother 1970; 10:296-302.
23. Gold GN, Richardson AP. An unusual case of neuromuscular blockade seen with therapeutic blood levels of colistin methanesulfonate. Am J Med 1966;41:316-21.
24. Olsen S, Madsen PO. Intravenous administration of sodium colistimethate in urinary tract infections. Curr Ther Res 1967;9:283-7.
25. Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. BMJ 1967;2:543-5.
26. Halliday NP. Pseudomonas infection of the respiratory tract treated with colistin sulphomethate sodium. Clin Trials J 1967;4:771-5.
27. Parry MF, Neu HC, Merlino M, Gaerlan PF, Oref CN, Denning CR. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr 1977;90:144-8.
28. Michalsen H, Bergan T. Azlocillin with and without an aminoglycoside against respiratory tact infections in children with cystic fibrosis. Scand J Infect Dis 1981; 29(Suppl):92-7.
29. McLaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147:559-67.
30. Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 1982;100:312-8.
31. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988;35:542-78.
32. Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Clin Pharmacokinet 1993;24: 496-506.